Ozempic after bariatric surgery: what the evidence says about weight regain

What's this video probably claiming?

Based on the caption, this creator had bariatric surgery nine years ago, regained most or all of the weight, cycled through multiple medications without lasting success, and is now trying semaglutide (Ozempic) alongside another drug she calls 'rita' (likely rimonabant or, more plausibly in the Brazilian market, a compounded formulation). She reports losing 5kg in the early phase and frames this as one more attempt in a long battle. The combination of 'ozem e rita' suggests she may be taking semaglutide alongside a second weight-related compound, possibly a cannabinoid receptor antagonist or another off-label agent used in Brazilian obesity clinics. The implicit claim is that GLP-1 therapy is working where bariatric surgery and prior medications failed her.

What does the science actually show?

Weight regain after bariatric surgery is not a personal failure. It is a documented physiological pattern. Pories et al. and longer-term follow-up data from the SOS study (Sjostrom, 2012, New England Journal of Medicine) confirm that up to 30-50% of bariatric patients regain significant weight within 5-10 years. The gut hormone adaptations that made surgery work gradually reset. GLP-1 receptor agonists target some of those same pathways. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced 14.9% mean body weight reduction over 68 weeks in adults with obesity. More relevant here, a 2022 retrospective study by Lautenbach et al. in Obesity Surgery found that post-bariatric patients on semaglutide lost an additional 7-10% of body weight over roughly 6 months, though results varied widely. Early losses of 5kg in the first few weeks are common and consistent with the known front-loaded weight loss pattern of GLP-1 therapy.

Where does the social media noise diverge from clinical reality?

The post-bariatric GLP-1 story on social media tends to flatten a complicated clinical picture. What gets left out: semaglutide dosing in post-bariatric patients is not straightforward. Absorption can be altered after procedures like Roux-en-Y gastric bypass, and gastrointestinal side effects may be amplified in this population. Shukla et al. (2019, Obesity Reviews) documented that GLP-1 levels are already elevated after bypass surgery, which means adding exogenous GLP-1 agonist therapy may hit a different baseline than in a non-surgical patient. The 'two medications' framing is worth flagging too. Stacking semaglutide with unverified compounded agents, which are common in Brazilian aesthetic medicine clinics, is not something a responsible provider should do without careful oversight. No one should take that combination based on what performs well on TikTok.

What should you actually know?

If you've had bariatric surgery and regained weight, you're not alone and you're not broken. The biology genuinely works against long-term maintenance in many patients. GLP-1 receptor agonists have real, published evidence for this specific population and are increasingly used in post-bariatric weight regain protocols. But five kilograms in a few weeks is the easy part. The STEP trials and bariatric-specific data show that meaningful, sustained results require months of dose titration, consistent use, and lifestyle support. The 'rita' medication mentioned in this video is unverifiable from the caption alone, and stacking Ozempic with any second agent without proper clinical supervision raises real safety questions. Early wins on TikTok look great. The 12-month data is where the truth lives.